In a 3-0 ruling, the 3rd US Circuit Court of Appeals in Philadelphia restored the claims of several hundreds of plaintiffs against Merck for their osteoporosis drug Fosamax, according to Reuters. The plaintiffs claim the company didn’t adequately warn of the risk of thigh bone fractures that the drug may carry. Trials can now proceed on failure-to-warn claims, which a lower court originally found to be pre-empted ...
Appeals Court Restores Cases Against Merck Over Fosamax
Posted May 2, 2017 in Drug and Medical Device Lawsuits | Product News and Recalls
Merck To Pay Additional $23 Million To End Vioxx Litigation
Posted August 23, 2013 in Product News and Recalls
On November 9, 2007 Merck agreed to a $4.85 billion global settlement in the Vioxx litigation. Bloomberg reports that Merck has now agreed to pay another $23 million for allegedly misleading their customers into buying their drug.
Customers are uniting in nationwide group litigation contending that “Merck officials sold Vioxx for unapproved uses and made false statements about its cardiovascular safety.” In other words, they were duped into buying the painkiller and now feel they ...
continue reading...
